Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,238 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Sale · Disposed 25,000 · Balance 39,238 |
| Common StockSEC Table I · non-derivative | IndirectBy spouse revocable trust | 60,000 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 60,000 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 20,873 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 3,336 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $155.01 · Expires 2025-05-06 | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-21 · Disposition to issuer · Disposed 2,343 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $167.97 · Expires 2024-07-22 | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-21 · Disposition to issuer · Disposed 2,706 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $138.86 · Expires 2026-05-11 | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-21 · Disposition to issuer · Disposed 2,294 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 3,336 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
Innocoll Holdings plc
Report date July 24, 2017 · Filed July 26, 2017
Section 16 reporting ended · disclosed 2017-07-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-07-24 · Disposition to issuer · Disposed 237,440 · Balance 0 F1: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 237,440 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares"). F2: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30 | Direct | 0 |
Reported balance
After 2017-07-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-24 · Disposition to issuer · Disposed 11,659 · Balance 0 F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30 | Direct | 0 |
Reported balance
After 2017-07-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-24 · Disposition to issuer · Disposed 8,230 · Balance 0 F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30 | Direct | 0 |
Reported balance
After 2017-07-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-24 · Disposition to issuer · Disposed 14,907 · Balance 0 F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 237,440 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares").
F2: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings.
F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 25,000 | $124.00 | $3,100,000.00 |
DisclosureSEC source: 0001609305-26-000009 · wk-form4_1789157083.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,238 Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:07 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 3,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609305-26-000004 · wk-form4_1778875632.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,238 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on the first anniversary of the grant date (the Vesting Date), provided that the director (a) remains a member of the Board of Directors of the issuer until the earlier of (i) such Vesting Date and (ii) the Company's Annual Shareholder Meeting in the year of such Vesting Date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 13, 2026, for no consideration. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609305-26-000002 · wk-form4_1772053457.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,933 Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:42 UTC | INSMED Inc INSM · Entity 3174 | GiftCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609305-25-000004 · wk-form4_1762810957.xml · nonDerivative · entry 2 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse revocable trust Disclosed balance after: 60,000 Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:42 UTC | INSMED Inc INSM · Entity 3174 | GiftCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609305-25-000004 · wk-form4_1762810957.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,933 Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:57 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-026569 · wk-form4_1747688264.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,933 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 15, 2025 for no consideration. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:17 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023560 · wk-form4_1715804216.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,875 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:21 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018200 · wf-form4_168418208788013.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,713 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2023, for no consideration. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:16 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019182 · form4.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,521 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2022, for no consideration. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:27 UTC | INSMED Inc INSM · Entity 3174 | PurchaseCommon Stock | 10,000 | $30.15 | $301,500.00 |
DisclosureSEC source: 0001140361-21-036422 · form4.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,876 Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,294 | $138.86 Strike: $138.86 | $318,544.84 |
DisclosureSEC source: 0000899866-21-000070 · wf-form4_162707303457502.xml · derivative · entry 4 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 2,294 shares Expires 2026-05-11 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,706 | $167.97 Strike: $167.97 | $454,526.82 |
DisclosureSEC source: 0000899866-21-000070 · wf-form4_162707303457502.xml · derivative · entry 3 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 2,706 shares Expires 2024-07-22 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,343 | $155.01 Strike: $155.01 | $363,188.43 |
DisclosureSEC source: 0000899866-21-000070 · wf-form4_162707303457502.xml · derivative · entry 2 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 2,343 shares Expires 2025-05-06 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerCommon Stock, par value $.0001 per share | 20,873 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000070 · wf-form4_162707303457502.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 3,336 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000040 · wf-form4_162188793114273.xml · nonDerivative · entry 2 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,873 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 1,962 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000040 · wf-form4_162188793114273.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,499 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:27 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 7,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017417 · form4.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,876 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2021 for no consideration. Read SEC document |
| May 14, 2020 Filed May 18, 2020 17:22 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,428 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000050 · wf-form4_158983693305646.xml · nonDerivative · entry 2 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,537 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of the annual cash retainer that the director was entitled to receive for service as a director. Read SEC document |
| May 14, 2020 Filed May 18, 2020 17:22 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 3,468 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000050 · wf-form4_158983693305646.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,109 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the earlier of (i) the first anniversary of the grant date and (ii) the date of the 2021 Annual Shareholder Meeting. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:57 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 8,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-061851 · a4.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,318 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2020 for no consideration. Read SEC document |
| May 15, 2019 Filed May 16, 2019 21:16 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-19-000075 · edgar.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,221 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the vesting date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2019, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:42 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 1,908 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000073 · wf-form4_155812572607727.xml · nonDerivative · entry 2 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,641 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of the annual cash retainer that the director was entitled to receive for service as a director. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:42 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000073 · wf-form4_155812572607727.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,733 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:13 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-18-000038 · edgar.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,322 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 09, 2018 Filed May 11, 2018 16:16 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000096 · wf-form4_152606971378414.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,007 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 23:04 UTC | Innocoll Holdings plc INNL · Entity 12261 | Disposition to issuerStock Option (right to buy) · Derivative | 14,907 | Not disclosed Strike: $8.80 | Not disclosed |
DisclosureSEC source: 0001144204-17-038449 · v471498_4.xml · derivative · entry 4 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 14,907 shares Expires 2026-03-30 F3 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 23:04 UTC | Innocoll Holdings plc INNL · Entity 12261 | Disposition to issuerStock Option (right to buy) · Derivative | 8,230 | Not disclosed Strike: $8.80 | Not disclosed |
DisclosureSEC source: 0001144204-17-038449 · v471498_4.xml · derivative · entry 3 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 8,230 shares Expires 2026-03-30 F3 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 23:04 UTC | Innocoll Holdings plc INNL · Entity 12261 | Disposition to issuerStock Option (right to buy) · Derivative | 11,659 | Not disclosed Strike: $8.80 | Not disclosed |
DisclosureSEC source: 0001144204-17-038449 · v471498_4.xml · derivative · entry 2 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 11,659 shares Expires 2026-03-30 F3 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 23:04 UTC | Innocoll Holdings plc INNL · Entity 12261 | Disposition to issuerOrdinary Shares, par value $0.01 per share | 237,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-038449 · v471498_4.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 237,440 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares"). F2 · price: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings. F2 · balance_after: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:28 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-17-000041 · edgar.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,256 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was received as a grant on May 17, 2017, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 10, 2017 Filed May 12, 2017 18:00 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000109 · wf-form4_149462642188594.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,833 F1 · shares: RSU's will vest 100% on the 1-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.